News & Conferences

Please find our latest company or product news and keep abreast of new developments.

PAST CONFERENCES

April 2020:

2^nd – 3^rd April 2020: Meet our company’s CSO Geert Mudde, PhD, at the 4^th Annual Drug Discovery Summit in Munich, Germany

May 2020:

21^st – 22^nd May 2020: Meet our company’s CSO Geert Mudde, PhD, at the Oxford Global: Immuno Series UK: Autoimmunity & Immunology Congress in London, UK

June 2020:

22^nd – 23^rd June 2020: Meet our company’s CSO Geert Mudde, PhD, at the 3^rd International Conference on Allergy, Asthma & Immunology in Berlin, Germany
30^th June 2020: Meet our company’s CSO Geert Mudde, PhD, at the Oncology & Bioinformatics Strategy Meeting in London, UK

March 2020:

19^th March 2020: Meet our company’s CSO Geert Mudde, PhD, at the Oxdord Global: Immuno Series UK Pre-Event Webinar

October 2019:

29^th – 31^st October 2019: Meet our company’s CSO Geert Mudde, PhD, at the World Vaccine Congress in Barcelona Spain
22^nd October 2019: Meet our company’s CSO Geert Mudde, PhD, at the European Immuno-Oncology Xchange in Zurich, Switzerland
9^th October 2019: Meet our company’s CSO Geert Mudde, PhD, at the 2^nd Cell & Gene Therapy Strategy Meeting in Zurich, Switzerland

September 2019:

20^th September 2019: Meet our company’s CSO Geert Mudde, PhD, at Lachen gegen Krebs in Brunn am Gebirge, Austria

May 2019:

23^rd – 24^th May 2019: Meet our company’s CSO Geert Mudde, PhD, at the 3^rd Drug discovery Nexus in Munich, Germany
20^th – 21^st May 2019: Meet our company’s CSO Geert Mudde, PhD,at the 4^th Annual Advances in Immuno-Oncology UK Congress in London, UK

April 2019:

24^th – 25^th April 2019: Meet our company’s CSO Geert Mudde, PhD, at the 9th World Congress on Breastcancer in London, UK

March 2019:

13^th March 2019: Meet our company’s CSO Geert Mudde, PhD, at the Oncology Strategy Meeting Europe 2019 in Munich, Germany

December 2018:

6^th – 7^th December 2018: Meet our company’s CSO Geert Mudde, PhD, at the International Congress on Vaccines & Immunology in Amsterdam, Netherlands
4^th – 5^th December 2018: Meet our company’s former Head of Business Development, Monika Olschak, at the BioFIT Conference in Lille, France

November 2018:

29^th – 30^th November 2018: Meet our company’s CSO Geert Mudde, PhD, at the 6^th Drug Discovery Innovation Programme in Frankfurt, Germany
6^th – 7^th November 2018: Meet our company’s CSO Geert Mudde, PhD, at the International Congress on Vaccines & Immunology in Amsterdam, The Netherlands
5^th – 7^th November 2018: Meet our company’s former Head of Business Development, Monika Olschak, at Bio Europe in Copenhagen, Denmark

October 2018:

29^th – 31^st October 2018: Meet our company’s CSO Geert Mudde, PhD, at the 19^th World Vaccine Congress Europe in Lisbon, Portugal
17^th – 18^th October 2018: Meet our company’s former Head of Business Development, Monika Olschak, at the European Business Development Conference in Hanover, Germany
3^rd – 5^th October 2018: Meet our company’s CSO Geert Mudde, PhD, at the Immuno Oncology Summit in Vienna, Austria

September 2018:

26^th September 2018: Meet our company’s CSO Geert Mudde, PhD, at the 1^st Cell and Gene Therapy Meeting in Zürich, Switzerland
18^th – 19^th September 2018: Meet our company’s CSO Geert Mudde, PhD, at the 6^th European Biopharma Congress in Amsterdam, Netherlands

June 2018:

28^th June 2018: Meet our company’s CSO Geert Mudde, PhD, at the European Immuno-Oncology Round Table Meeting in Zürich, Switzerland

May 2018

24^th– 25^thMay 2018: Meet our company’s CSO Geert Mudde, PhD, at the 3^rd Annual Advances in Immuno-Oncology Congress in London, UK
22^nd May 2018: Meet our company’s CSO Geert Mudde, PhD, at the 5^th Oncology Strategy Meeting Europe in Munich, Germany

14^th – 16^th May 2018: Meet our company’s former Head of Business Development, Monika Olschak, at the 19^th Annual Bio€quity Europe in Ghent, Belgium

April 2018:

25^th – 26^th April 2018: Meet our company’s CEO, Christof Langer, at the ChinaBio® in Suzhou, China
24^nd – 25^th April 2018: Meet our company’s CSO Geert Mudde, PhD, at the 3^rdAnnual Advances in Immuno-Oncology Congress in London, UK
16^th – 17^th April 2018: Meet our company’s CSO Geert Mudde, PhD, at the 5^th Annual Peptide Conference in London, UK

November 2017:

9^th – 10^th November 2017: Meet our company’s CSO Geert Mudde, PhD, at the 21^st World Congress and Exhibition on Vaccines, Vaccination & Immunization in Vienna, Austria
9^th – 11^th November 2017: We present OncoQR ML’s unique S-TIR™ immunotherapy platform technology at the 4^th European Biopharma Congress in Vienna, Austria
6^th – 8^th November 2017: Meet OncoQR ML’s former Business Development Manager Monika Olschak at one of the largest and most important Life Science Business Partnering conferences, the BIO EUROPE 2017 in Berlin, Germany

October 2017:

11^th – 12^th October 2017: OncoQR ML’s CSO Geert Mudde, PhD, takes part in the round table discussion at the Genesis Drug Discovery Program in Frankfurt, Germany
10^th – 11^th Oct 2017: Geert Mudde, PhD, and Kathrin Szimak look forward to meet you for business partnering and presenting at the European Business Development Conference in Heidelberg, Germany

September 2017:

5^th – 8^th September 2017: OncoQR ML`s CSO Geert Mudde, PhD, presents at 46^th EuroCongress on Drug Synthesis and Analysis on in Bratislava, Slovak Republic

May 2017:

19^th – 21^st May 2017: Meet OncoQR ML`s co-founder and CSO Geert Mudde, PhD, at BITs 10^th Annual World Cancer Congress 2017 (WCC 2017) on in Barcelona, Spain
15^th – 16^th May 2017: OncoQR ML presents at 2^nd Annual Advances in Immune-Oncology Congress, London, UK

PRESS RELEASES

September 2017:

OncoQR ML’s Vaccine Platform closes the Final Gap in the Immunological Attack against Cancer

October 2015:

OncoQR’s Breast Cancer Vaccine Successfully Completes Pre-Clinical Proof-of-Concept Study

News & Conferences

News & Conferences

PAST CONFERENCES

PRESS RELEASES

September 2017:

OncoQR ML’s Vaccine Platform closes the Final Gap in the Immunological Attack against Cancer

October 2015:

OncoQR’s Breast Cancer Vaccine Successfully Completes Pre-Clinical Proof-of-Concept Study